<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886353</url>
  </required_header>
  <id_info>
    <org_study_id>APN01-1-01</org_study_id>
    <nct_id>NCT00886353</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)</brief_title>
  <official_title>Double-blind, Placebo-controlled Dose-escalation Phase I Study With Recombinant Human Soluble Angiotensin Converting Enzyme 2 (rhACE2) APN01 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apeiron Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apeiron Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to define the dose for a Phase II study and to investigate&#xD;
      safety and tolerability of intravenous administration of recombinant soluble human&#xD;
      Angiotensin Converting Enzyme 2 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      APN01-1-01 is a placebo controlled double blinded Phase I study composed of a single dose,&#xD;
      dose escalation part followed by a multiple dosage part. The first four cohorts (four&#xD;
      individuals each) will receive 100, 200, 400 and 800 µg/kg APN01 i.v. or placebo. Cohorts 5&#xD;
      and 6 (three individuals each) will receive three and six i.v. APN01 administrations daily,&#xD;
      respectively. Planned dosage of the multiple dose part will be 400 µg/kg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability profile of APN01 when administered as a single dose / multiple dose i.v. in healthy volunteers. Measures: Blood chemistry, Hematology, Urinalysis, Adverse events, Vital signs including blood pressure, pulse, respiratory rate, ECG</measure>
    <time_frame>31 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To obtain pharmacokinetic and pharmacodynamic data for APN01 and to investigate potential immunogenicity of APN01. Measures: Systemic rhACE2 concentration and activity, potential humoral immune response, Angiotensin II and Angiotensin 1-7 plasma levels.</measure>
    <time_frame>31 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Pulmonary Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Kidney Diseases</condition>
  <condition>Cancer Diseases</condition>
  <arm_group>
    <arm_group_label>APN01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers will receive APN01</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiological saline administrated i.v.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>APN01</intervention_name>
    <description>APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.</description>
    <arm_group_label>APN01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Physiological saline administrated i.v.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Use of acceptable form of birth control&#xD;
&#xD;
          -  Willing to comply with study protocol&#xD;
&#xD;
          -  No significant background illness&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant hematological, renal, hepatic, metabolic, psychiatric or pulmonary&#xD;
             diseases.&#xD;
&#xD;
          -  Heart disease or elevated blood pressure.&#xD;
&#xD;
          -  Any other significant disease that could interfere with the subject's ability to&#xD;
             complete the protocol&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Abnormal urinalysis&#xD;
&#xD;
          -  Pregnant or lactating female subjects&#xD;
&#xD;
          -  Use of anticoagulants or antihypertensive drugs, particularly drugs interfering with&#xD;
             the renin-angiotensin-aldosterone system, Obesity or anorexia (BMI &lt;18 or &gt;30)&#xD;
&#xD;
          -  History of malignancy, except basal cell carcinoma of the skin, Known history of human&#xD;
             immunodeficiency virus (HIV), hepatitis B or hepatitis C infection or positive&#xD;
             serology testing in the study screening procedures (except indicating immunization)&#xD;
&#xD;
          -  Participation in a clinical trial within the last 30 days&#xD;
&#xD;
          -  Any of the following laboratory abnormalities:&#xD;
&#xD;
               -  WBC 15% outside of normal limits&#xD;
&#xD;
               -  Hemoglobin 15% outside of normal limits&#xD;
&#xD;
               -  Platelets 15% outside of normal limits&#xD;
&#xD;
               -  Aspartate transferase (AST) or alanine transferase (ALT) above 15% outside of&#xD;
                  normal limits&#xD;
&#xD;
               -  Alkaline phosphatase above 15% outside of normal limits&#xD;
&#xD;
               -  Urea above 15% outside of normal limits&#xD;
&#xD;
               -  Creatinine above 15% outside of normal limits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Kraehenbuehl, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <last_update_submitted>December 30, 2009</last_update_submitted>
  <last_update_submitted_qc>December 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Krähenbühl, Chefarzt klinische Pharmakologie &amp; Toxikologie</name_title>
    <organization>Universitätsspital 4031 Basel</organization>
  </responsible_party>
  <keyword>RAS</keyword>
  <keyword>ACE2</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Angiotensin II</keyword>
  <keyword>Angiotensin 1-7</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

